Bjørn Naume

5PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 25, 2025
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy.

Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen

|Jun 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.

Andreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde

|Nov 15, 2024
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer.

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold

|Jul 09, 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen

|Dec 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.

Hope S Rugo, Catherine H Van Poznak, Patrick Neven

Pageof 1

Frequent Collaborators

4 joint publications

Jon Amund Kyte

3 joint publications

Andreas Hagen Røssevold

3 joint publications

Nikolai Kragøe Andresen

1 joint publications

Hope S Rugo